Xenon Pharmaceuticals Inc.

XENEReported to SECin USCIK 0001582313Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 7. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 7
Form 4 lines at Xenon Pharmaceuticals Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Kelly Thomas PatrickChief Financial OfficerOpen-market buy$559,74015,000 sharesOct 1, 2026Kelly Thomas PatrickChief Financial Officer$559,740Buy · Oct 1Open-market buy15,000Oct 1, 2026
MORTIMER IANPRESIDENT & CEOOpen-market buy$1,121,40030,000 sharesOct 1, 2026MORTIMER IANPRESIDENT & CEO$1,121,400Buy · Oct 1Open-market buy30,000Oct 1, 2026
Svoronos Dawn—Option exercisenothing paid5,144 sharesSep 3, 2026Svoronos Dawnnothing paidExercise · Sep 3Option exercise5,144Sep 3, 2026
Svoronos Dawn—Option exercise$41,9245,144 sharesSep 3, 2026Svoronos Dawn$41,924Exercise · Sep 3Option exercise5,144Sep 3, 2026
KENNEY CHRISTOPHER JOHNChief Medical OfficerOpen-market sell$42,684700 sharesAug 31, 2026KENNEY CHRISTOPHER JOHNChief Medical Officer$42,684Sell · Aug 31Open-market sell700Aug 31, 2026